Intra-Cellular Therapies Inc. (ITCI) is set for a tempting yields with an average volume of 741.06K

Let’s start up with the current stock price of Intra-Cellular Therapies Inc. (ITCI), which is $30.81 to be very precise. The Stock rose vividly during the last session to $18.94 after opening rate of $17.76 while the lowest price it went was recorded $17.50 before closing at $18.43.

Recently in News on September 9, 2020, Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression. Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) in late 2020 or early 2021. You can read further details here

Intra-Cellular Therapies Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $34.31 on 01/02/20, with the lowest value was $10.94 for the same time period, recorded on 03/18/20.

Intra-Cellular Therapies Inc. (ITCI) full year performance was 78.41%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intra-Cellular Therapies Inc. shares are logging -29.27% during the 52-week period from high price, and 356.44% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.75 and $43.56.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 15929776 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Intra-Cellular Therapies Inc. (ITCI) recorded performance in the market was -46.28%, having the revenues showcasing -16.79% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.25B, as it employees total of 330 workers.

The Analysts eye on Intra-Cellular Therapies Inc. (ITCI)

During the last month, 0 analysts gave the Intra-Cellular Therapies Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 21.13, with a change in the price was noted +12.60. In a similar fashion, Intra-Cellular Therapies Inc. posted a movement of +72.54% for the period of last 100 days, recording 892,206 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ITCI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of Intra-Cellular Therapies Inc. (ITCI)

Raw Stochastic average of Intra-Cellular Therapies Inc. in the period of last 50 days is set at 89.26%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 89.26%. In the last 20 days, the company’s Stochastic %K was 49.02% and its Stochastic %D was recorded 33.28%.

Considering, the past performance of Intra-Cellular Therapies Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -46.28%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -5.34%, alongside a boost of 78.41% for the period of the last 12 months. The shares increased approximately by 1.15% in the 7-day charts and went up by -11.86% in the period of the last 30 days. Common stock shares were lifted by -16.79% during last recorded quarter.